KAI-4169: Phase II data

A double-blind, dose-escalation, U.S. Phase II trial in 78 patients with chronic kidney disease-mineral and bone disorder (CKD-MBD) showed that thrice-weekly 5 and 10 mg IV KAI-4169 given during hemod...